Syed Shah, MD
Nephrology · Las Vegas, NVNPI 1639369630
Payments from drug & device makers
Across 16 payments — averaging $57.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$234
- Nxstage Medical, Inc.$202
- Veloxis Pharmaceuticals, Inc.$100
- Otsuka America Pharmaceutical, Inc.$95
- Abiomed$94
- Merck$48
- plus $141 from 5 others
What the payments were for
- Food & beverage$81589%
- Education$10011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 3 | $234 |
| Nxstage Medical, Inc. | 2 | $202 |
| Veloxis Pharmaceuticals, Inc. | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 1 | $95 |
| Abiomed | 1 | $94 |
| Merck | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Amgen | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$122
- NXSTAGE SYSTEM ONE$104
How this compares
$915 in reported general payments places this provider in the 35th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 13 | $915,838 |
| SolirisEculizumab | 12 | $617,688 |
| Valganciclovir Hcl | 35 | $16,509 |
| Cinacalcet Hcl | 45 | $15,469 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $11,611 |
| Tacrolimus | 42 | $8,053 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 15 | $2,141 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,652 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,430 |
| Prednisone | 147 | $1,069 |
| Nifedipine ErNifedipine | 22 | $702 |
| Mycophenolate Mofetil | 12 | $587 |
| Hydralazine Hcl | 29 | $522 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 13 | $498 |
| Metoprolol Tartrate | 50 | $445 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Las Vegas
- Mark VishnepolskyLas Vegas$11.3M
- Raj SinghLas Vegas$9.9M
- Samuel KantorLas Vegas$1M
- Jeffrey RyuLas Vegas$422K
- Lawrence LehrnerLas Vegas$239K
- Richard CottieroLas Vegas$220K
- Kamron SaleemLas Vegas$195K
- Mark AdaimyLas Vegas$142K
- Vincent YangLas Vegas$135K
- Prateek SangheraLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.